Duloxetine in the treatment of burning mouth syndrome refractory to conventional treatment: A case report

Kim, Yeon-Dong; Lee, Jihye; Shim, Jee-Hoon

doi:10.1177/0300060514527913

Cited by 16 publications

(11 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, two single case reports and one observational study with small number of subjects have reported the effects of SNRIs on BMS patients [19][20][21].…”

Section: Discussionmentioning

confidence: 99%

“…Duloxetine tends to have better analgesic effects at higher doses, and the recommended dose of duloxetine is generally 60 mg once daily [15]. In two single case reports, 60 mg/day of duloxetine was effective in refractory BMS patients [20,21].…”

Section: Discussionmentioning

confidence: 99%

“…However, no studies have examined the efficacy of venlafaxine alone. Although the beneficial effects of duloxetine on refractory BMS have been documented in two studies [20,21], both studies are single case reports. In addition, another study reported contradictory results that the oral symptoms of one patient who was prescribed duloxetine did not improve [22].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Treatment Outcomes of Venlafaxine and Duloxetine in Refractory Burning Mouth Syndrome Patients

Kim

Kho

2019

JOMP

View full text Add to dashboard Cite

Purpose: Venlafaxine and duloxetine have been shown to be effective in the treatment of neuropathic pain disorders. However, knowledge about the efficacy of venlafaxine and duloxetine on burning mouth syndrome (BMS) is still insufficient. The purpose of this study was to investigate the efficacy of venlafaxine and duloxetine on refractory BMS patients. Methods:Twelve refractory BMS patients who were prescribed venlafaxine or duloxetine were included in this study. These patients did not respond to previous administration of clonazepam, alpha-lipoic acid, gabapentin, and nortriptyline. All participants were the primary type of BMS patients who had no local and systemic factors related to the oral burning sensation. The intensities of oral symptoms following venlafaxine or duloxetine administration were compared with those before administration and at baseline.Results: Venlafaxine and duloxetine were prescribed to four and nine patients, respectively. One patient was prescribed both medications in turn. Among them, only two patients showed improvement of oral symptoms without side effects. In the other ten patients, symptoms failed to improve. Six of them reported that the drug was ineffective, and four of them stopped taking the medications on their own due to intolerable side effects, such as insomnia, constipation, drowsiness, dizziness, and xerostomia.Conclusions: Venlafaxine and duloxetine may only relieve oral symptoms in a minority of refractory BMS patients. Further large-scale studies are needed to determine the potential clinical factors that could predict the efficacy of venlafaxine and duloxetine.

show abstract

“…In fact, two single case reports and one observational study with small number of subjects have reported the effects of SNRIs on BMS patients [19][20][21].…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment Outcomes of Venlafaxine and Duloxetine in Refractory Burning Mouth Syndrome Patients

Kim

Kho

2019

JOMP

View full text Add to dashboard Cite

show abstract

“…The effectiveness of many pharmacological agents, including pregabalin, 18) topiramate, 19) duloxetine, 20) pramipexol, 21) and olanzapine, 22,23) has been reported in isolated cases or case series. In the present study, we reported the effectiveness of new pharmacologic agents that had not been discussed previously in the literature.…”

Section: Discussionmentioning

confidence: 99%

Retrospective Review of Effectiveness of Various Pharmacological Agents in Treating Burning Mouth Syndrome

Im¹,

Kim²,

Kim³

2016

Journal of Oral Medicine and Pain

View full text Add to dashboard Cite

Purpose: Burning mouth syndrome (BMS) is a chronic pain condition involving the oral and perioral regions, often characterized by a burning sensation and pain in elderly patients. In this study, we investigated the effectiveness of pharmacological agents for the treatment of BMS patients through a retrospective chart review. Methods:We enrolled 61 BMS subjects (57 females, 4 males; 66.4±10.9 years of age) from among consecutive patients treated pharmacologically from January 2014 to June 2015 at Chonnam National University Dental Hospital. Patients with secondary BMS associated with local factors were excluded. The treatment period, number of pharmacological agents tried, and effectiveness of the drugs administered to each subject were analyzed. Results:The mean treatment period for the management of BMS was 2.5 months. More than three agents were tried to control BMS symptoms in 17 subjects (27.9%); two agents were used in 10 subjects (16.4%), and a single agent in 24 subjects (39.3%). Clonazepam was prescribed most frequently and was effective at relieving symptoms in 30 of 39 subjects (76.9%). Paroxetine was moderately effective, relieving symptoms in 7 of 17 subjects (41.2%). Some of the subjects benefited from tricyclic antidepressants, gabapentin, and lipoic acid. A topical local anesthetic used to supplement other systemic agents had ameliorating effects in four of six subjects. Conclusions:Within the study limitations, clonazepam was the most effective drug and antidepressants were efficacious in some subjects for relieving the symptoms of BMS. These pharmacological agents could be considered as first-line drugs for the management of BMS.

show abstract

“…Treatment modalities for BMS patients according to the literature are summarized in Table 1. 75,[90][91][92][93][94][95][96][97][98][99][100][101][102][103][104][105][106][107] Furthermore, Kuten-Shorrer et al evaluated the placebo effect in 12 published RCTs regarding the treatment of BMS. Despite limitations of the studies (study design, sample size, duration of therapy, placebo control), they found a positive placebo response in 6 out of 12 studies.…”

Section: Managementmentioning

confidence: 99%

Burning mouth syndrome – a burning enigma

Rogulj

Brzak

Boras

et al. 2021

Med. Flum. (Online)

View full text Add to dashboard Cite

Burning Mouth Syndrome (BMS) is a chronic pain condition characterized by an intraoral burning sensation and an absence of oral mucosal lesions and disturbances in laboratory findings. Burning symptoms usually affect the anterior two-thirds of the tongue, its lateral borders, hard palate and labial mucosa, but other oral cavity sites may also be affected. Taste alterations and a decrease in the salivary flow rate frequently accompany the burning symptoms. This condition mostly affects peri- and postmenopausal women. To date, the etiology of BMS remains unclear. This unknown etiology means that no appropriate treatment is currently available. A large number of the treatments and medications have been tried for BMS, but treatment management remains unsatisfactory in some patients. The purpose of this article is to present current knowledge on the treatment of BMS.

show abstract

Duloxetine in the treatment of burning mouth syndrome refractory to conventional treatment: A case report

Cited by 16 publications

References 20 publications

Treatment Outcomes of Venlafaxine and Duloxetine in Refractory Burning Mouth Syndrome Patients

Treatment Outcomes of Venlafaxine and Duloxetine in Refractory Burning Mouth Syndrome Patients

Retrospective Review of Effectiveness of Various Pharmacological Agents in Treating Burning Mouth Syndrome

Burning mouth syndrome – a burning enigma

Contact Info

Product

Resources

About